Vertex Pharmaceuticals (VRTX) | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Vertex Pharmaceuticals (VRTX)

An SI Board Since August 1996

Posts	SubjectMarks	Bans	Symbol
1169	64	0	VRTX

Emcee: David Lieberman	Type: Unmoderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
869	The stock is going crazy. Over 44 for awhile, now to 41.	Rocky9	-	10/27/2006
868	Tables all screwed up. Here is the link for them: vpharm.com New Data for Inv	kenhott	-	10/27/2006
867	Too bad I didn't listen to myself and buy the breakout and not before! Stil	Tom Caruthers	-	10/20/2006
866	It could have something to do with today’s FDA advisory panel on HCV: fda.gov	DewDiligence_on_SI	-	10/20/2006
865	what happened here, down on volume, I can not find any news on VRTX to explain i	OpusX	-	10/20/2006
864	Looks like VRTX is trying to break out here from a technical perspective. Chart	Tom Caruthers	-	10/20/2006
863	Yes, it might. VRTX/J&J, NVS/IDIX, SGP,...will need to work hard to gain res	Miljenko Zuanic	-	10/16/2006
862	Apart from ITMN's Hep C drug,Roche also has Maxy Alpha which might make a po	dr.praveen	-	10/16/2006
861	Excellent deal for ITMN HCV program, at pre-clinical stage. Roche is HCV market	Miljenko Zuanic	-	10/16/2006
860	I suppose that is why the stock goes down some 4% on a day like today.	idos	-	9/12/2006
859	I didn't see this posted elsewhere? I certainly missed this yesterday. Ver	LJM	-	9/12/2006
858	UBS report is available for the asking: investorshub.com	DewDiligence_on_SI	-	8/30/2006
857	RESEARCH ALERT-UBS raises Vertex to buy August 25, 2006 08:27:02 (ET) (Change	LJM	-	8/25/2006
856	Head-to-Head Study Comparing LEXIVA(R) (Fosamprenavir Calcium) to Kaletra Presen	LJM	-	8/17/2006
855	quid, the valuation is at a $3.5B market cap, there's only so high it should	rkrw	-	8/12/2006
854	I'm not thrilled with the stock action here either. Even if someone had insi	JamesK	-	8/11/2006
853	The JNJ deal was overrated, IMO. A lot of people went gaga over VRTX’s retaining	DewDiligence_on_SI	-	8/10/2006
852	The stock sure trades like crap following the announcement of the JNJ deal. If	quidditch	-	8/10/2006
851	Vertex Pharmaceuticals Announces Agreements to Exchange Common Stock for $58.3 M	LJM	-	8/3/2006
850	Merrill (neutral) Uneventful quarter; Increasing R&D spending on VX-950 In	tom pope	-	7/27/2006
849	I'm thinking all this may wind up to an "early" good... Hoping at	LJM	-	7/26/2006
848	VX-950 notes from VRTX CC: investorshub.com	DewDiligence_on_SI	-	7/26/2006
847	VRTX :Vertex Signed Major EU Partnership With J&J 2006-06-30 11:31 (New York	mopgcw	-	7/12/2006
846	CC comments: Royalty mid-20s. 2nd generation 950 a couple or more years behin	rkrw	-	7/3/2006
845	And now Merrill is heard from (Rating is neutral): Attractive partnership with	tom pope	-	6/30/2006

Go to reply# or date (mm/dd/yy):